Nimatpagene pariparvovec

帕哌内基

Report date: 2023/12/29 11:51:14

Base Information

Drug NameNimatpagene pariparvovec
Drug Alias NameVTX-801
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionCopper-transporting ATPase 2 gene transference
TargetsCopper-transporting ATPase 2
Therapy Area/IndicationsHepatolenticular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVivet Therapeutics SAS
China Registration ClassN/A

Develop Information

Active CompaniesVivet Therapeutics SASPfizer Inc
Inactive CompaniesN/A
Active IndicationsHepatolenticular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A